Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–436.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li N, Zhang S, et al. Emerging carrier-free nanosystems based on molecular self-assembly of pure drugs for cancer therapy. Med Res Rev. 2020;40(5):1754–1775.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Cuhna AS, Caramella C, et al.; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):56–68.
   PubMed Web of Science ®Google Scholar
• Si J, Zhao X, Gao S, Huang D, Sui M. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin. Int J Pharm. 2019;568:118499.
   PubMed Web of Science ®Google Scholar
• Milano G, Innocenti F, Minami H. Liposomal irinotecan (Onivyde): exemplifying the benefits of nanotherapeutic drugs. Cancer Sci. 2022;113(7):2224–2231.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27(16):2604–2614.
   PubMed Web of Science ®Google Scholar
• Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev. 2011;63(3):184–192.
   PubMed Web of Science ®Google Scholar
• Huang Q, Liu X, Wang H, et al. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer. Acta Biomater. 2022;137:262–275.
   PubMed Web of Science ®Google Scholar
• Musetti S, Huang L. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy. ACS Nano. 2018;12(12):11740–11755. doi:10.1021/acsnano.8b05893
   PubMed Web of Science ®Google Scholar
• Chen Q, Liu G, Liu S, et al. Remodeling the tumor microenvironment with emerging nanotherapeutics. Trends Pharmacol Sci. 2018;39(1):59–74. doi:10.1016/j.tips.2017.10.009
   PubMed Web of Science ®Google Scholar
• Sapra P, Kraft P, Mehlig M, et al. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin’s lymphoma. Haematologica. 2009;94(10):1456–1459. doi:10.3324/haematol.2009.008276
   PubMed Web of Science ®Google Scholar
• Koizumi F, Kitagawa M, Negishi T, et al. Novel SN-38–incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor–secreting bulky tumors. Cancer Res. 2006;66(20):10048–10056. doi:10.1158/0008-5472.CAN-06-1605
   PubMed Web of Science ®Google Scholar
• Wang S, Ye T, Yang B, Yi X, Yao H. 7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in-vivo evaluation. Drug Dev Ind Pharm. 2013;39(2):393–401. doi:10.3109/03639045.2012.683441
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al.; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, Phase 3 trial. Lancet. 2016;387(10018):545–557.
   PubMed Web of Science ®Google Scholar
• Ganipineni LP, Danhier F, Préat V. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. J Control Release. 2018;281:42–57.
   PubMed Web of Science ®Google Scholar
• Li G, Sun B, Li Y, Luo C, He Z, Sun J. Small-molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery. Small. 2021;17(52):e2101460.
   PubMed Web of Science ®Google Scholar
• Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.
   PubMed Web of Science ®Google Scholar
• Xiao H, Guo Y, Liu H, et al. Structure-based design of charge-conversional drug self-delivery systems for better targeted cancer therapy. Biomaterials. 2020;232:119701.
   PubMed Web of Science ®Google Scholar
• Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351–370.
   PubMed Web of Science ®Google Scholar
• Yu W, Liu R, Zhou Y, Gao H. Size-tunable strategies for a tumor targeted drug delivery system. ACS Cent Sci. 2020;6(2):100–116.
   PubMed Web of Science ®Google Scholar
• Li H, Zhao Y, Jia Y, Qu C, Li J. Covalently assembled dopamine nanoparticle as an intrinsic photosensitizer and pH-responsive nanocarrier for potential application in anticancer therapy. Chem Commun. 2019;55(100):15057–15060.
   PubMed Web of Science ®Google Scholar
• Dong S, He J, Sun Y, et al. Efficient click synthesis of a protonized and reduction-sensitive amphiphilic small-molecule prodrug containing camptothecin and gemcitabine for a drug self-delivery system. Mol Pharm. 2019;16(9):3770–3779.
   PubMedGoogle Scholar
• Wang Y, Huang P, Hu M, Huang W, Zhu X, Yan D. Self-delivery nanoparticles of amphiphilic methotrexate-gemcitabine prodrug for synergistic combination chemotherapy via effect of deoxyribonucleotide pools. Bioconjug Chem. 2016;27(11):2722–2733.
   PubMed Web of Science ®Google Scholar
• Fu LH, Wan Y, Qi C, et al. Nanocatalytic theranostics with glutathione depletion and enhanced reactive oxygen species generation for efficient cancer therapy. Adv Mater. 2021;33(7):e2006892.
   PubMed Web of Science ®Google Scholar
• Yeh CC, Hou MF, Wu SH, et al. A study of glutathione status in the blood and tissues of patients with breast cancer. Cell Biochem Funct. 2006;24(6):555–559.
   PubMed Web of Science ®Google Scholar
• Grubben MJ, van den Braak CC, Nagengast FM, Peters WH. Low colonic glutathione detoxification capacity in patients at risk for colon cancer. Eur J Clin Invest. 2006;36(3):188–192.
   PubMed Web of Science ®Google Scholar
• Gupta A, Srivastava S, Prasad R, et al. Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology. 2010;15(2):349–356.
   PubMed Web of Science ®Google Scholar
• Kearns PR, Pieters R, Rottier MM, Pearson AD, Hall AG. Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 2001;97(2):393–398.
   PubMed Web of Science ®Google Scholar
• Zhong X, Wang X, Cheng L, et al. GSH depleted PtCu3 nanocages for chemodynamicenhanced sonodynamic cancer therapy. Adv Funct Mater. 2019;30:1907954–1907966.
   Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579–591.
   PubMed Web of Science ®Google Scholar
• Noh J, Kwon B, Han E, et al. Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death. Nat Commun. 2015;6:6907.
   PubMed Web of Science ®Google Scholar
• Song P, Yao X, Zhong T, et al. The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug. Oncotarget. 2016;7(30):48467–48480.
   PubMedGoogle Scholar
• Duan XC, Yao X, Zhang S, et al. Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo. Int J Nanomedicine. 2018;14:195–204.
   PubMed Web of Science ®Google Scholar
• Duan XC, Peng LY, Yao X, et al. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. Drug Deliv. 2021;28(1):800–813.
   PubMed Web of Science ®Google Scholar
• Zhong T, Hao YL, Yao X, et al. Effect of XlogP and Hansen solubility parameters on small molecule modified paclitaxel anticancer drug conjugates self-assembled into nanoparticles. Bioconjug Chem. 2018;29(2):437–444.
   PubMed Web of Science ®Google Scholar
• Xu MQ, Zhong T, Yao X, et al. Effect of XlogP and Hansen solubility parameters on the prediction of small molecule modified docetaxel, doxorubicin and irinotecan conjugates forming stable nanoparticles. Drug Deliv. 2021;28(1):1603–1615.
   PubMed Web of Science ®Google Scholar
• Cheng T, Zhao Y, Li X, et al. Computation of octanol-water partition coefficients by guiding an additive model with knowledge. J Chem Inf Model. 2007;47(6):2140–2148.
   PubMed Web of Science ®Google Scholar
• Barton AFM. CRC Handbook of Solubility Parameters and Other Cohesion Parameters. 2nd ed. Boca Raton: CRC Press; 1991.
   Google Scholar
• Hansen CM. Hansen Solubility Parameters: A User’s Handbook. 2nd ed. Boca Raton: CRC Press; 2007.
   Google Scholar
• Zhang S, Li ZT, Liu M, et al. Anti-tumour activity of low molecular weight heparin doxorubicin nanoparticles for histone H1 high-expressive prostate cancer PC-3M cells. J Control Release. 2019;295:102–117.
   PubMed Web of Science ®Google Scholar
• Xu MQ, Hao YL, Wang JR, et al. Antitumor activity of α-linolenic acid-paclitaxel conjugate nanoparticles: in vitro and in vivo. Int J Nanomedicine. 2021;16:7269–7281.
   PubMed Web of Science ®Google Scholar
• Behzadi S, Serpooshan V, Tao W, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev. 2017;46(14):4218–4244.
   PubMed Web of Science ®Google Scholar
• Taketani M, Shii M, Ohura K, Ninomiya S, Imai T. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci. 2007;81(11):924–932.
   PubMed Web of Science ®Google Scholar
• Di L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab. 2019;20(2):91–102.
   PubMed Web of Science ®Google Scholar
• Dong Z, Feng L, Chao Y, et al. Amplification of tumor oxidative stresses with liposomal Fenton catalyst and glutathione inhibitor for enhanced cancer chemotherapy and radiotherapy. Nano Lett. 2019;19(2):805–815.
   PubMed Web of Science ®Google Scholar
• Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov. 2018;17(8):559–587.
   PubMed Web of Science ®Google Scholar
• Bildstein L, Dubernet C, Couvreur P. Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev. 2011;63(1–2):3–23.
   PubMed Web of Science ®Google Scholar
• Huttunen KM, Raunio H, Rautio J. Prodrugs--from serendipity to rational design. Pharmacol Rev. 2011;63(3):750–771.
   PubMed Web of Science ®Google Scholar
• Bariwal J, Kumar V, Chen H, et al. Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment. J Control Release. 2019;309:231–243.
   PubMed Web of Science ®Google Scholar
• Liu Y, Shen G, Zhao L, Zou Q, Jiao T, Yan X. Robust photothermal nanodrugs based on covalent assembly of nonpigmented biomolecules for antitumor therapy. ACS Appl Mater Interfaces. 2019;11(45):41898–41905.
   PubMed Web of Science ®Google Scholar
• Vangara KK, Ali HI, Lu D, Liu JL, Kolluru S, Palakurthi S. SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer. AAPS Pharm Sci Tech. 2014;15(2):472–482.
   PubMed Web of Science ®Google Scholar
• Salmanpour M, Yousefi G, Samani SM, Mohammadi S, Anbardar MH, Tamaddon A. Nanoparticulate delivery of irinotecan active metabolite (SN38) in murine colorectal carcinoma through conjugation to poly (2-ethyl 2-oxazoline)-b-poly (L-glutamic acid) double hydrophilic copolymer. Eur J Pharm Sci. 2019;136:104941.
   PubMed Web of Science ®Google Scholar
• Liu B, Wang D, Liu Y, et al. Hydrogen peroxide-responsive anticancer hyperbranched polymer micelles for enhanced cell apoptosis. Polym Chem. 2015;6:3460–3471.
   Web of Science ®Google Scholar
• Vijayalakshmi N, Ray A, Malugin A, Ghandehari H. Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation. Bioconjug Chem. 2010;21(10):1804–1810.
   PubMed Web of Science ®Google Scholar
• Yao Y, Su X, Xie Y, et al. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate. Anticancer Drugs. 2013;24(3):270–277.
   PubMed Web of Science ®Google Scholar
• Palakurthi S. Challenges in SN38 drug delivery: current success and future directions. Expert Opin Drug Deliv. 2015;12(12):1911–1921.
   PubMed Web of Science ®Google Scholar
• Du Y, Zhang W, He R, et al. 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects. Bioorg Med Chem. 2017;25(12):3247–3258.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen J, Xu C, et al. Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations. Theranostics. 2017;7(15):3638–3652.
   PubMed Web of Science ®Google Scholar
• Kasai H, Murakami T, Ikuta Y, et al. Creation of pure nanodrugs and their anticancer properties. Angew Chem Int Ed Engl. 2012;51(41):10315–10318.
   PubMed Web of Science ®Google Scholar
• Nguyen F, Alferiev I, Guan P, et al. Enhanced intratumoral delivery of SN38 as a tocopherol oxyacetate prodrug using nanoparticles in a neuroblastoma xenograft model. Clin Cancer Res. 2018;24(11):2585–2593.
   PubMed Web of Science ®Google Scholar
• Botta L, Filippi S, Zippilli C, et al. Artemisinin derivatives with antimelanoma activity show inhibitory effect against human DNA topoisomerase 1. ACS Med Chem Lett. 2020;11(5):1035–1040.
   PubMed Web of Science ®Google Scholar
• Jiang X, Lee M, Xia J, et al. Two-stage SN38 release from a core-shell nanoparticle enhances tumor deposition and antitumor efficacy for synergistic combination with immune checkpoint blockade. ACS Nano. 2022;16:1.
   Google Scholar
• Dong X, Brahma RK, Fang C, Yao SQ. Stimulus-responsive self-assembled prodrugs in cancer therapy. Chem Sci. 2022;13(15):4239–4269.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Böttger R, Li SD. Recent trends in bioresponsive linker technologies of prodrug-based self-assembling nanomaterials. Biomaterials. 2021;275:120955.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, Deng F, et al. The effect of linkers on the self-assembling and anti-tumor efficacy of disulfide-linked doxorubicin drug-drug conjugate nanoparticles. J Control Release. 2018;279:136–146.
   PubMed Web of Science ®Google Scholar
• Cai K, He X, Song Z, et al. Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency. J Am Chem Soc. 2015;137(10):3458–3461.
   PubMed Web of Science ®Google Scholar
• Muniesa C, Vicente V, Quesada M, et al. Glutathione-sensitive nanoplatform for monitored intracellular delivery and controlled release of Camptothecin. RSC Adv. 2013;3(35):15121–15131.
   Web of Science ®Google Scholar
• Yang C, Tu K, Gao H, et al. The novel platinum (IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer. Biomaterials. 2020;232:119751.
   PubMed Web of Science ®Google Scholar
• Dey J, Ghosh R, Das Mahapatra R. Self-assembly of unconventional low-molecular-mass amphiphiles containing a PEG chain. Langmuir. 2019;35(4):848–861.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu D, Zheng Q, et al. Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines. Nano Lett. 2014;14(10):5577–5583.
   PubMed Web of Science ®Google Scholar
• Lin W, Sun T, Xie Z, Gu J, Jing X. A dual-responsive nanocapsule via disulfide-induced self-assembly for therapeutic agent delivery. Chem Sci. 2016;7(3):1846–1852.
   PubMed Web of Science ®Google Scholar
• Yang Y, Sun B, Zuo S, et al. Trisulfide bond-mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity. Sci Adv. 2020;6(45):eabc1725.
   PubMed Web of Science ®Google Scholar
• Luo C, Sun J, Sun B, et al. Facile fabrication of tumor redox-sensitive nanoassemblies of small-molecule oleate prodrug as potent chemotherapeutic nanomedicine. Small. 2016;12(46):6353–6362.
   PubMed Web of Science ®Google Scholar
• Wang J, Mao W, Lock LL, et al. The role of micelle size in tumor accumulation, penetration, and treatment. ACS Nano. 2015;9(7):7195–7206.
   PubMed Web of Science ®Google Scholar
• Kim CS, Li X, Jiang Y, et al. Cellular imaging of endosome entrapped small gold nanoparticles. MethodsX. 2015;2:306–315.
   PubMedGoogle Scholar
• Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 2001;41:53–77.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002;8(3):641–661.
   PubMed Web of Science ®Google Scholar